| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/02/2004 | US20040171115 Comprises hematopoietic protein modulator for use in proliferation and diffefrentiation of bone marrow cells |
| 09/02/2004 | US20040171113 Antigens of group b streptococcus and corresponding dna fragments |
| 09/02/2004 | US20040171111 Polypeptide of a p53 protein-specific murin a/t-cell receptor, nucleic acids coding therefor and use thereof |
| 09/02/2004 | US20040171109 Comprises nucleotide sequences coding interleukin receptor protein for use in the diagnosis, prevention and treatment of bone disorders; gene therapy |
| 09/02/2004 | US20040171105 Using enzymatic polypeptide to inactivate inhibitor of apoptosis and activate caspase for treatment and prevention of cancer, autoimmune and neurodegenerative diseases |
| 09/02/2004 | US20040171103 Process for the production of a reversibly inactive acidified plasmin composition |
| 09/02/2004 | US20040171073 Modulators which prevent lipid transport via blocking activity of scavenger receptors and for treating atheroscerotic disosrders; contraceptives |
| 09/02/2004 | US20040171066 Template-fixed peptidomimetics with antimicrobial activity |
| 09/02/2004 | US20040171059 Comprises nucleotide sequences coding enzymatic polypeptide associated with programed cell death for identifying modulators for treatment of inflammatory, neurodegenerative and cell proliferative disorders |
| 09/02/2004 | US20040171058 Preparing chimeric ribozyme for use in treatment of viral diseases; viricides |
| 09/02/2004 | US20040171037 Using genic copy number of oncogenes to diagnose, prevent and treat tumor disorders; antitumor agents |
| 09/02/2004 | US20040171033 Comprises modified nucleotide sequences for use in gene expression inhibition, viral defense, transposon silencing and treatment of metabolic disorders; antisense agents |
| 09/02/2004 | US20040171031 Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| 09/02/2004 | US20040171030 Oligonucleotide sequences capable of binding RNA-induced silencing complexes for use in treatment and prevention of metabolic and cell proliferative disorders |
| 09/02/2004 | US20040171018 Mouse farnesoid x receptor sequences for use in comparative pharmacology |
| 09/02/2004 | US20040171012 Nucleic acid-associated proteins |
| 09/02/2004 | US20040171009 Lipid-associated molecules |
| 09/02/2004 | US20040170999 Nuclear hormone receptor ligand binding domain |
| 09/02/2004 | US20040170997 used in drug screening for preventing or treating diseases associated with abnormalities in intracellular signal transduction; genetic engineering |
| 09/02/2004 | US20040170995 for drug screening in vitro for mitogen-activated protein kinase-activated protein kinase-2 modulators using expression libraries; genetic engineering; kits |
| 09/02/2004 | US20040170994 DNA sequences for human tumour suppressor genes |
| 09/02/2004 | US20040170993 Methods for diagnosing and treating heart disease |
| 09/02/2004 | US20040170973 DNA encoding the human serine protease EOS |
| 09/02/2004 | US20040170972 comprises DNA vaccine, a recombinant vaccine, and a T cell epitope vaccine; includes use of serological diagnosis; genetic engineering |
| 09/02/2004 | US20040170971 kits for detecting amplification or elevated expression for diagnosis; genetic engineering; solid phase synthesis |
| 09/02/2004 | US20040170963 for gene expression inhibition drugs; genetic engineering |
| 09/02/2004 | US20040170961 for drug screening anticancer agents; solid phase synthesis; animal models; genetic engineering; kits |
| 09/02/2004 | US20040170960 Lectin compositions and methods for modulating an immune response to an antigen |
| 09/02/2004 | US20040170959 Methods for identifying antiviral oligonucleotides |
| 09/02/2004 | US20040170955 Human and mouse targeting peptides identified by phage display |
| 09/02/2004 | US20040170713 To promote good health and as a dietary additive |
| 09/02/2004 | US20040170665 Intravitreal botulinum toxin implant |
| 09/02/2004 | US20040170654 bolus injection to skin; increased systemic absorption produced compared to absorption produced on delivering the agonist subcutaneously by bolus injection; particularly applicable to tricyclic nitrogen-containing compounds, e.g., R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinoline-2(1H)-thione |
| 09/02/2004 | US20040170653 recognised by CD8-positive cytotoxic T-lymphocytes as a peptide antigen and causes a CTL-induced lysis and/or apoptosis of tumor or leukemia cell; has the amino acid sequence LLGDLFGV, which corresponds to the amino acid positions 81 to 88 of the hdm2 proto-oncoprotein |
| 09/02/2004 | US20040170651 In vivo modulation of neuronal transport |
| 09/02/2004 | US20040170641 Prevention and treatment of amyloidogenic disease |
| 09/02/2004 | US20040170635 administering an inhibitor of the CD2/LFA-3 interaction, in combination with narrow band UVB radiation; especially for treating psoriasis |
| 09/02/2004 | US20040170631 Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodies |
| 09/02/2004 | US20040170625 administration of an Epidermolysis Bullosa-inhibiting polypeptide comprising amino acid sequence LKKTET that is actin-sequestering, such as Thymosin beta 4, an isoform of Thymosin beta 4 or oxidized Thymosin beta 4. |
| 09/02/2004 | US20040170622 Methods and compositions for modulating XBP-1 activity |
| 09/02/2004 | US20040170619 contacting a nucleic acid binding polypeptide, preferably a zinc finger polypeptide, with a nucleic acid sequence in the primary cell to regulate its expression; |
| 09/02/2004 | US20040170618 antagonists bind to a recognized target (e.g., a receptor); the enzyme component of the chimera then degrades the target resulting in a reduction of activity of the target and release of the chimeric molecule, which is then free to attack and degrade another target molecule. |
| 09/02/2004 | US20040170613 Compositions and methods for liver growth and liver protection |
| 09/02/2004 | US20040170611 culturing an autologous or allogenic dermal papilla cell in the presence of a Wnt polypeptide or a fragment or analog thereof, and grafting the cultured cell onto the skin |
| 09/02/2004 | US20040170610 Compositions comprising bone marrow cells together with demineralized and/or mineralized bone matrix and uses thereof in the induction of bone and cartilage formation |
| 09/02/2004 | US20040170605 Activation gene expression of slug gene; transplant or gene therapy; sexual disorders; fertility |
| 09/02/2004 | US20040170604 Genetic engineering; yeast culture product; blood platelet proliferative agents |
| 09/02/2004 | US20040170603 Using radiolabeled annexin; radiotherapy for tumors |
| 09/02/2004 | US20040170602 Dominant negative proteins and methods thereof |
| 09/02/2004 | US20040170601 Administering cytokines |
| 09/02/2004 | US20040170598 Polysubstituted polycarboxylic phosphoamide biopolymers, methods for their production and uses of compositions derived therefrom |
| 09/02/2004 | US20040170595 Multi-arm block copolymers as drug delivery vehicles |
| 09/02/2004 | US20040170590 Water-soluble silk proteins in compositions for skin care, hair care or hair coloring |
| 09/02/2004 | DE10306452A1 New peptides containing tyrosine sulfate, phosphate or sulfonate derivatives, useful against unwanted skin and hair pigmentation and for lightening hair color |
| 09/02/2004 | DE10306083A1 Erkennungsmoleküle gerichtet gegen ein Survivin-Gen und die Verwendung dieser Recognition molecules directed against a survivin gene and the use of these |
| 09/02/2004 | DE10304994A1 Die Verwendung von Antagonisten des Bradykinin-B2 Rezeptors zur Behandlung von Osteoarthrose The use of antagonists of bradykinin B2 receptor for the treatment of osteoarthritis |
| 09/02/2004 | CA2753408A1 Production of modified glycoproteins having multiple antennary structures |
| 09/02/2004 | CA2714863A1 Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom |
| 09/02/2004 | CA2517006A1 Methods for the treatment and prevention of diseases of biological conduits |
| 09/02/2004 | CA2516971A1 Secreted chlamydia polypeptides, polynucleotides coding therefor, therapeutic and diagnostic uses thereof |
| 09/02/2004 | CA2516945A1 Therapeutic agent for spinal cord injury comprising interleukin-6 antagonist |
| 09/02/2004 | CA2516777A1 Human cyclooxygenase-3 enzyme and uses thereof |
| 09/02/2004 | CA2516685A1 Peptidomimetic inhibitors of stat3 activity and their medical uses |
| 09/02/2004 | CA2516550A1 Production of modified glycoproteins having multiple antennary structures |
| 09/02/2004 | CA2516520A1 N-acetylglucosaminyltransferase iii expression in lower eukaryotes |
| 09/02/2004 | CA2516486A1 Method of treating ischemic disease |
| 09/02/2004 | CA2516453A1 Composition and methods for inhibiting cell survival |
| 09/02/2004 | CA2516320A1 Induced activation in dendritic cells |
| 09/02/2004 | CA2516293A1 Fusion proteins of interferon alpha muteins with improved properties |
| 09/02/2004 | CA2516290A1 Methods of diagnosis and prognosis of pancreatic cancer |
| 09/02/2004 | CA2516282A1 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
| 09/02/2004 | CA2516259A1 Anti-angiogenic and anti-tumoral properties of beta and gamma secretase inhibitors |
| 09/02/2004 | CA2516172A1 Anticancer agent comprising lk8 protein as an active ingredient |
| 09/02/2004 | CA2516080A1 Inhibitors of antigen presentation by mhc class ii molecules and methods of use thereof |
| 09/02/2004 | CA2515965A1 Inhibition of tace or amphiregulin for the modulation of egf receptor signal transactivation |
| 09/02/2004 | CA2515779A1 Contraceptive method and compositions related to proteasomal interference |
| 09/02/2004 | CA2515515A1 Mtor kinase-associated proteins |
| 09/02/2004 | CA2515033A1 Clk-peptide and slk-peptide |
| 09/02/2004 | CA2514485A1 Compositions comprising fetal hemoglobin and bacterial endotoxin and optionally additional fetal liver components |
| 09/02/2004 | CA2514061A1 Combination therapy for the treatment of immunoinflammatory disorders |
| 09/02/2004 | CA2513307A1 Analogues of glp-1 |
| 09/01/2004 | EP1452868A2 Method for selecting a candidate drug compound |
| 09/01/2004 | EP1452600A1 Receptor and nucleic acid molecule encoding said receptor |
| 09/01/2004 | EP1452599A1 Improved epitope displaying phage |
| 09/01/2004 | EP1452594A1 Inducer for differentiation of embryo stem cells into ectodermal cells, method of obtaining the same and use thereof |
| 09/01/2004 | EP1452542A2 Reshaped human monoclonal antibodies specific for IgE |
| 09/01/2004 | EP1452541A1 Hepatitis e virus monoclonal antibodies or the binding fragments of it and the use thereof |
| 09/01/2004 | EP1452532A1 Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 09/01/2004 | EP1452205A1 Uses of keratinocyte growth factor-2 |
| 09/01/2004 | EP1452184A1 Use of thioester-containing proteins (TEPs) for triggering/inducing an immune response in mosquitoes of Anopheles against plasmodium malariae |
| 09/01/2004 | EP1452183A1 Use of PGRP, LRRP and CTL proteins to trigger an anti-Plasmodium immune response in Anopheles species |
| 09/01/2004 | EP1452182A1 Angiogenesis drugs |
| 09/01/2004 | EP1452181A1 Regulation of immune responses by manipulation of intermediary metabolite levels |
| 09/01/2004 | EP1451856A2 Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells |
| 09/01/2004 | EP1451590A2 Peptides and method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases |
| 09/01/2004 | EP1451587A2 Antigen panels and methods of using the same |
| 09/01/2004 | EP1451578A2 Composition comprising and method of using angiopoietin-like protein 3 angptl3 |
| 09/01/2004 | EP1451577A2 Soluble cd40l(cd154) as a prognostic marker of atherosclerotic diseases |
| 09/01/2004 | EP1451576A2 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 09/01/2004 | EP1451571A2 Dosing and administration of therapeutic micro-organs in living subjects and devices and methods for same |